S17 Ep38: FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE
In today’s episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.
In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.